RenovoRx, Inc. Banner Image

RenovoRx, Inc.

  • Ticker RNXT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
RenovoRx, Inc. Logo Image
  • 1-10 Employees
  • Based in Los Altos, California
RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical needs. The Company’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to bypass traditional systemic delivery methods and ensure precise therapeutic delivery to a target tissue, while minimizing a therapy’s systemic toxicities. RenovoRx’sMore unique approach to drug-delivery offers the potential for increased treatment safety, tolerance, and wider therapeutic windows. The Company’s lead product candidate, RenovoGem™ combines gemcitabine with the company’s patented delivery system and is regulated by FDA under the IND 21 CFR 312 pathway. RenovoGem is currently in a Phase III clinical trial (TIGeR-PaC) for the treatment of locally advanced pancreatic cancer, where interim analysis has demonstrated a 6-month overall survival benefit, 8-month delay in cancer progression, and 65% reduction in adverse effects over systemic (intravenous) chemotherapy. RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.
5.0 / 5.0 (1)

RenovoRx, Inc. reports have an aggregate usefulness score of 5.0 based on 1 reviews.

RenovoRx, Inc.

Most Recent Annual Report

RenovoRx, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

RenovoRx, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!